PharmaCyte Biotech Inc (PMCB)

NASDAQ
Currency in USD
1.0800
-0.0166(-1.51%)
Closed·
After Hours
1.1100+0.0300(+2.7778%)
·
PMCB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PMCB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.06001.1400
52 wk Range
1.00002.4229
Key Statistics
Edit
Prev. Close
1.0966
Open
1.06
Day's Range
1.06-1.14
52 wk Range
1-2.4229
Volume
21.61K
Average Volume (3m)
11.01K
1-Year Change
-48.08%
Book Value / Share
5.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PMCB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

PharmaCyte Biotech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

PharmaCyte Biotech Inc Company Profile

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Compare PMCB to Peers and Sector

Metrics to compare
PMCB
Peers
Sector
Relationship
P/E Ratio
0.7x−4.2x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.2x1.7x2.6x
Price / LTM Sales
-16.1x3.2x
Upside (Analyst Target)
-154.6%45.4%
Fair Value Upside
Unlock9.4%6.9%Unlock

Earnings

Latest Release
Jul 02, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PMCB Income Statement

People Also Watch

65.71
ES
-0.61%
21.43
TDC
-3.77%
89.34
ANF
+1.25%
13.68
NOV
-0.58%
20.90
THS
-0.19%

FAQ

What Stock Exchange Does PharmaCyte Biotech Trade On?

PharmaCyte Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for PharmaCyte Biotech?

The stock symbol for PharmaCyte Biotech is "PMCB."

What Is the PharmaCyte Biotech Market Cap?

As of today, PharmaCyte Biotech market cap is 7.42M.

What Is PharmaCyte Biotech's Earnings Per Share (TTM)?

The PharmaCyte Biotech EPS (TTM) is 1.29.

When Is the Next PharmaCyte Biotech Earnings Date?

PharmaCyte Biotech will release its next earnings report on 24 Aug 2025.

From a Technical Analysis Perspective, Is PMCB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has PharmaCyte Biotech Stock Split?

PharmaCyte Biotech has split 2 times.

How Many Employees Does PharmaCyte Biotech Have?

PharmaCyte Biotech has 2 employees.

What is the current trading status of PharmaCyte Biotech (PMCB)?

As of 13 Jul 2025, PharmaCyte Biotech (PMCB) is trading at a price of 1.08, with a previous close of 1.10. The stock has fluctuated within a day range of 1.06 to 1.14, while its 52-week range spans from 1.00 to 2.42.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.